Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted predominantly by intestinal enteroendocrine L cells in response to nutrient ingestion. By enhancing insulin secretion, delaying ...

THURSDAY, May 15, 2025 (HealthDay News) -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity ...

Rates of metabolic and bariatric surgeries (MBS) rose by almost 15% in teenagers in the US between 2021 and 2023, despite falling in adults, new research has found. The cross-sectional analysis, ...

More information: Yael Wolff Sagy et al, Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Weight loss drugs like Ozempic have gained a lot of popularity However these medications are not without side effects One ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Glucagon-like peptide 1 (GLP-1) receptor agonists were developed for managing type 2 diabetes. By mimicking the action of the hormone GLP-1, they can reduce appetite, increase satiety and slow ...

They’ve all been used to describe effects of the rapid weight loss that can come from taking glucagon-like peptide-1 receptor agonists like semaglutide, which is in Ozempic.

People undergoing metabolic and bariatric surgery (MBS) are less likely to develop psychiatric disorders than those treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs).